Each quarter, The Leading Edge newsletter highlights new topics to give our referring physicians the latest news on leading-edge therapies that SCCA physicians are offering.2014 | 2013 | 2012 | | 2010 | 2009 | 2008
In this issue we are excited to present findings from a clinical study about a new enzymatic therapy for pancreas cancer. PEGPH20 is bringing hope to patients with an unforgiving disease as it makes it possible for chemotherapies to do their job. We have two interesting articles about bone marrow transplantation: one regarding the tricky balance of treating sickle cell disease and the other about making this life-saving treatment more accessible to older patients.
In this exciting summer issue, we report on our leading head and neck cancer care, ranked sixth among the top cancer centers in the nation and new therapies for Lung Cancer, Prostate Cancer, and Pancreas Cancer. Also, a recent article by SCCA researchers in the New England Journal of Medicine documents improved survival after allogeneic bone marrow transplantation over the past decade.
In this issue, we are pleased to announce FDA approval for Yervoy (ipilimumab), the first drug shown to prolong the lives of people with melanoma. This quarter we broke ground for a new Proton Therapy Center that is scheduled to open in 2013. A special event is planned in April for patients and families with Diamond-Blackfan Anemia. You can also read about Translational Research, the wave of the future for cancer treatment and the Seattle Cancer Consortium Breast SPORE (Specialized Program in Research Excellence) who received a sizeable award.
In this issue we invite you to read about our exciting alternative donor program for bone marrow transplants and how mini-transplants can help older patients or patients who may not be able to tolerate conventional high-dose conditioning. We’re also learning more and more about detecting lung cancer at earlier stages. This quarter, we talk about last November’s study from the National Cancer Institute that showed 20 percent fewer lung cancer deaths in people who were screened with low-dose spiral computed tomography compared with chest X-ray. And our prostate cancer feature focuses on Abiraterone, the latest breakthrough for treatment of advanced prostate cancer.
In 2011, Seattle Cancer Care Alliance will celebrate its 10th anniversary. We invite you to share your comments about SCCA on a community celebration Web site: www.sccatenyear.org. We’ll also be breaking ground for a new proton beam therapy center this year.
2014 | 2013 | 2012 | | 2010 | 2009 | 2008